Cost-effectiveness of lipid-lowering therapy

被引：0
|
作者：
Visseren, F. L. J. [1 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Vasc Med, NL-3508 GA Utrecht, Netherlands
来源：
NETHERLANDS HEART JOURNAL | 2011年 / 19卷 / 02期
关键词：
D O I：
10.1007/s12471-011-0078-4
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：59 / 60
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of lipid-lowering therapy
    Wendland, G
    Klever-Deichert, G
    Lauterbach, K
    HERZ, 2001, 26 (08) : 552 - 560
  • [2] Maximizing the cost-effectiveness of lipid-lowering therapy
    Jacobson, TA
    Schein, JR
    Williamson, A
    Ballantyne, CM
    ARCHIVES OF INTERNAL MEDICINE, 1998, 158 (18) : 1977 - 1989
  • [3] Cost-effectiveness of lipid-lowering treatment according to lipid level
    Pilote, L
    Ho, V
    Lavoie, F
    Coupal, L
    Zowall, H
    Grover, SA
    CANADIAN JOURNAL OF CARDIOLOGY, 2005, 21 (08) : 681 - 687
  • [4] Cost-Effectiveness of Intensive Lipid-Lowering in Young Adulthood
    Kohli-Lynch, Ciaran N.
    Bellows, Brandon K.
    Moran, Andrew E.
    Zhang, Yiyi
    Wilkins, John T.
    Allen, Norrina B.
    Lloyd-Jones, Donald M.
    CIRCULATION, 2024, 149
  • [5] Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults
    Kohli-Lynch, Ciaran N.
    Bellows, Brandon K.
    Zhang, Yiyi
    Spring, Bonnie
    Kazi, Dhruv S.
    Pletcher, Mark J.
    Vittinghoff, Eric
    Allen, Norrina B.
    Moran, Andrew E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (20) : 1954 - 1964
  • [6] Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
    Michaeli, Daniel Tobias
    Michaeli, Julia Caroline
    Boch, Tobias
    Michaeli, Thomas
    CARDIOVASCULAR DRUGS AND THERAPY, 2023, 37 (04) : 683 - 694
  • [7] Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany
    Daniel Tobias Michaeli
    Julia Caroline Michaeli
    Tobias Boch
    Thomas Michaeli
    Cardiovascular Drugs and Therapy, 2023, 37 : 683 - 694
  • [8] Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
    Ning Kam
    Kanila Perera
    Ella Zomer
    Danny Liew
    Zanfina Ademi
    PharmacoEconomics, 2020, 38 : 1007 - 1020
  • [9] Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis
    Kam, Ning
    Perera, Kanila
    Zomer, Ella
    Liew, Danny
    Ademi, Zanfina
    PHARMACOECONOMICS, 2020, 38 (09) : 1007 - 1020
  • [10] The Determinants of Cost-Effectiveness Potential: An Historical Perspective on Lipid-Lowering Therapies
    Rodrigo Refoios Camejo
    Clare McGrath
    Marisa Miraldo
    Frans Rutten
    PharmacoEconomics, 2013, 31 : 445 - 454
12345